Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling.
Mizumori O, Zembutsu H, Kato Y, Tsunoda T, Miya F, Morizono T, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, Ozono S, Miki T, Naito S, Akaza H, Nakamura Y. Mizumori O, et al. Among authors: kato y. Exp Ther Med. 2010 Nov;1(6):955-961. doi: 10.3892/etm.2010.148. Epub 2010 Sep 10. Exp Ther Med. 2010. PMID: 22993625 Free PMC article.
A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer.
Kato Y, Zembutsu H, Takata R, Matsuura T, Kato R, Kanehira M, Iwasaki K, Yamada N, Katagiri T, Sugai T, Fujioka T, Nakamura Y, Obara W. Kato Y, et al. Among authors: kato r. Oncol Lett. 2018 Nov;16(5):5775-5784. doi: 10.3892/ol.2018.9330. Epub 2018 Aug 20. Oncol Lett. 2018. PMID: 30333861 Free PMC article.
Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.
Obara W, Karashima T, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Inoue K, Katagiri T, Shuin T, Nakamura Y, Fujioka T. Obara W, et al. Among authors: kato r, kato y. Cancer Immunol Immunother. 2017 Jan;66(1):17-24. doi: 10.1007/s00262-016-1915-5. Epub 2016 Oct 18. Cancer Immunol Immunother. 2017. PMID: 27757561 Free PMC article. Clinical Trial.
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Low SK, Fukunaga K, Takahashi A, Matsuda K, Hongo F, Nakanishi H, Kitamura H, Inoue T, Kato Y, Tomita Y, Fukasawa S, Tanaka T, Nishimura K, Uemura H, Hara I, Fujisawa M, Matsuyama H, Hashine K, Tatsugami K, Enokida H, Kubo M, Miki T, Mushiroda T. Low SK, et al. Among authors: kato y. PLoS One. 2016 Feb 25;11(2):e0148177. doi: 10.1371/journal.pone.0148177. eCollection 2016. PLoS One. 2016. PMID: 26914831 Free PMC article.
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.
Obara W, Hara I, Kato Y, Kato R, Inoue K, Sato F, Mimata H, Nakamura Y, Fujioka T. Obara W, et al. Among authors: kato r, kato y. Cancer Immunol Immunother. 2018 Sep;67(9):1371-1380. doi: 10.1007/s00262-018-2197-x. Epub 2018 Jul 3. Cancer Immunol Immunother. 2018. PMID: 29971464 Free PMC article. Clinical Trial.
8,725 results